A Study on the factors associated with continuing treatment with brexpiprazole in patients with schizophrenia using MENTAT

Not Applicable

• Conditions: Schizophrenia

• Registration Number: JPRN-UMIN000045075
• Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Brief Summary

Eight factors were extracted from the results of multivariate analysis using the Cox proportional hazards regression model. Of these, "symptoms other than positive symptoms (after 28 days)," "ECT," "time of BRX 2 mg dose increase," "key person (with contact information)," and "reports and crimes" had hazard ratios of 1 or greater, while "physical complications," "maximum pre-start CP-equivalent dose category 1 (200-400 mg)" and "hospital days" had hazard ratios less than 1.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-08-20
• Study Completion: 2021-08-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 37534

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with mood [affective] disorder, dementia, disorders of psychological development, or hyperactivity disorder at the time of Index date 2) Patients who have been treated with brexpiprazole less than 1 mg / day and more than 2 mg / day even once

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To exploratively study the factors affecting the continuing treatment duration in patients with schizophrenia who started treatment with brexpiprazole

Secondary Outcome Measures

Name	Time	Method
Treatment continuation rates with brexpiprazole